ADMA Biologics Stock Today

ADMA
 Stock
  

USD 3.37  0.02  0.60%   

Market Performance
4 of 100
Odds Of Distress
Less than 25
ADMA Biologics is trading at 3.37 as of the 7th of December 2022, a 0.60 percent up since the beginning of the trading day. The stock's open price was 3.345. ADMA Biologics has about a 25 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for ADMA Biologics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 7th of November 2022 and ending today, the 7th of December 2022. Click here to learn more.
CUSIP
000899104
Fiscal Year End
December
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
17th of October 2013
Category
Healthcare
Classification
Health Care
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. ADMA Biologics, Inc. The company has 196.78 M outstanding shares of which 21.74 M shares are presently shorted by private and institutional investors with about 6.76 trading days to cover. More on ADMA Biologics

Moving together with ADMA Biologics

+0.79ABBVAbbVie Inc Sell-off TrendPairCorr
+0.66BMYBristol-Myers Squibb Aggressive PushPairCorr

Moving against ADMA Biologics

-0.68PRGOPerrigo Company Sell-off TrendPairCorr
-0.64CDNACaredx Inc Buyout TrendPairCorr
-0.52CSBRChampions Oncology Earnings Call This WeekPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

ADMA Biologics Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. ADMA Biologics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding ADMA Biologics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
ADMA Biologics has very high historical volatility over the last 90 days
The company reported the previous year's revenue of 80.94 M. Net Loss for the year was (71.65 M) with profit before overhead, payroll, taxes, and interest of 1.17 M.
ADMA Biologics currently holds about 52.42 M in cash with (112.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.27.
ADMA Biologics has a frail financial position based on the latest SEC disclosures
Over 80.0% of the company shares are held by institutions such as insurance companies
Latest headline from news.google.com: Institutional investors are ADMA Biologics, Inc.s biggest bettors and were rewarded after last weeks US139m market cap gain - Simply Wall St
President CEO, DirectorAdam Grossman
Fama & French Classification
Average Analyst Recommendation
Analysts covering ADMA Biologics report their recommendations after researching ADMA Biologics' financial statements, talking to executives and customers, or listening in on ADMA Biologics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering ADMA Biologics. The ADMA Biologics consensus assessment is calculated by taking the average forecast from all of the analysts covering ADMA Biologics.
Strong Buy4 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of ADMA Biologics based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of ADMA Biologics financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares Diluted150.6 M139.6 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares150.6 M139.6 M
Significantly Up
Increasing
Slightly volatile
Current Liabilities32.8 M30.4 M
Significantly Up
Increasing
Slightly volatile
Total Liabilities145.7 M135.1 M
Significantly Up
Increasing
Slightly volatile
Gross Margin1.491.4495
Fairly Up
Decreasing
Slightly volatile
Total Debt103 M95.5 M
Significantly Up
Increasing
Slightly volatile
Asset Turnover0.290.3345
Fairly Down
Increasing
Slightly volatile
Current Assets225.2 M208.7 M
Significantly Up
Increasing
Slightly volatile
Total Assets298.1 M276.3 M
Significantly Up
Increasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of ADMA Biologics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Cautious HoldUndervalued
Financial Strength
ADMA Biologics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to ADMA Biologics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand ADMA Biologics' financial leverage. It provides some insight into what part of ADMA Biologics' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on ADMA Biologics' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how ADMA Biologics deploys its capital and how much of that capital is borrowed.
Liquidity
ADMA Biologics cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 94.87 M in liabilities with Debt to Equity (D/E) ratio of 1.32, which is about average as compared to similar companies. ADMA Biologics has a current ratio of 7.78, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist ADMA Biologics until it has trouble settling it off, either with new capital or with free cash flow. So, ADMA Biologics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like ADMA Biologics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for ADMA Biologics to invest in growth at high rates of return. When we think about ADMA Biologics' use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(115.33 Million)
ADMA Biologics (ADMA) is traded on NASDAQ Exchange in USA and employs 527 people. ADMA Biologics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 637.56 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate ADMA Biologics's market, we take the total number of its shares issued and multiply it by ADMA Biologics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. ADMA Biologics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 196.78 M outstanding shares of which 21.74 M shares are presently shorted by private and institutional investors with about 6.76 trading days to cover. ADMA Biologics currently holds about 52.42 M in cash with (112.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.27.
Check ADMA Biologics Probability Of Bankruptcy
Ownership
ADMA Biologics retains a total of 196.78 Million outstanding shares. The majority of ADMA Biologics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in ADMA Biologics to benefit from reduced commissions. Thereupon, institutional investors are subject to a different set of regulations than regular investors in ADMA Biologics. Please pay attention to any change in the institutional holdings of ADMA Biologics as this could imply that something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check ADMA Biologics Ownership Details

ADMA Biologics Stock Price Odds Analysis

What are ADMA Biologics' target price odds to finish over the current price? Depending on a normal probability distribution, the odds of ADMA Biologics jumping above the current price in 90 days from now is roughly 2.66%. The ADMA Biologics probability density function shows the probability of ADMA Biologics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.1625. This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, ADMA Biologics will likely underperform. Additionally, the company has an alpha of 0.1408, implying that it can generate a 0.14 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
  Odds Below 3.37HorizonTargetOdds Above 3.37
97.32%90 days
 3.37 
2.66%
Based on a normal probability distribution, the odds of ADMA Biologics to move above the current price in 90 days from now is roughly 2.66 (This ADMA Biologics probability density function shows the probability of ADMA Biologics Stock to fall within a particular range of prices over 90 days) .

ADMA Biologics Historical Income Statement

ADMA Biologics Income Statement is one of the three primary financial statements used for reporting ADMA Biologics's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of ADMA Biologics revenue and expense. ADMA Biologics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
ADMA Biologics Direct Expenses is projected to increase significantly based on the last few years of reporting. The past year's Direct Expenses was at 79.77 Million. The current year Cost of Revenue is expected to grow to about 86.1 M, whereas Consolidated Income is forecasted to decline to (73.5 M). View More Fundamentals

ADMA Biologics Stock Against Markets

Picking the right benchmark for ADMA Biologics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in ADMA Biologics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for ADMA Biologics is critical whether you are bullish or bearish towards ADMA Biologics at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in ADMA Biologics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Theme Ratings Now

   

Theme Ratings

Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

ADMA Biologics Corporate Directors

ADMA Biologics corporate directors refer to members of an ADMA Biologics board of directors. The board of directors generally takes responsibility for the ADMA Biologics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of ADMA Biologics' board members must vote for the resolution. The ADMA Biologics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Eric Richman - Independent DirectorProfile
Dov Goldstein - Independent DirectorProfile
Bernhard Ehmer - DirectorProfile
Bryant Fong - Independent DirectorProfile

Invested in ADMA Biologics?

The danger of trading ADMA Biologics is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of ADMA Biologics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than ADMA Biologics. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile ADMA Biologics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please continue to Trending Equities. You can also try Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Complementary Tools for analysis

When running ADMA Biologics price analysis, check to measure ADMA Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADMA Biologics is operating at the current time. Most of ADMA Biologics' value examination focuses on studying past and present price action to predict the probability of ADMA Biologics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move ADMA Biologics' price. Additionally, you may evaluate how the addition of ADMA Biologics to your portfolios can decrease your overall portfolio volatility.
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Is ADMA Biologics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA Biologics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADMA Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
637.6 M
Quarterly Revenue Growth YOY
0.987
Return On Assets
(0.11) 
Return On Equity
(0.69) 
The market value of ADMA Biologics is measured differently than its book value, which is the value of ADMA Biologics that is recorded on the company's balance sheet. Investors also form their own opinion of ADMA Biologics' value that differs from its market value or its book value, called intrinsic value, which is ADMA Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADMA Biologics' market value can be influenced by many factors that don't directly affect ADMA Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ADMA Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine ADMA Biologics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.